Evaluation of the JAK2 V617F gene mutation in myeloproliferative neoplasms cases: a one-center study from Eastern Anatolia

Gülbay G., YEŞİLADA E., ERKURT M. A., BAG H. G., KUKU İ., KAYA E.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, cilt.44, sa.4, ss.492-498, 2019 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1515/tjb-2018-0054
  • Dergi Adı: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.492-498
  • Anahtar Kelimeler: Janus Kinase2, JAK-STAT pathway, Myeloproliferative disorders, JAK2 V617F mutation, Real-time poly-merase chain reaction, TYROSINE KINASE JAK2, POLYCYTHEMIA-VERA, ESSENTIAL THROMBOCYTHEMIA, EXON-12 MUTATIONS, DISORDERS, FREQUENCY, ASSOCIATIONS, JAK2(V617F), PREVALENCE, PHENOTYPE
  • İnönü Üniversitesi Adresli: Evet

Özet

Objective: Detection of JAK2 V617F in myeloproliferative neoplasms (MPNs) is very important in both diagnosis and disease progression. In our study, we investigated the frequency of JAK2 V617F mutation in patients with myeloproliferative disorders.